Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma Meeting Abstract
| Authors: | Kumar, A.; Batlevi, C.; Drullinsky, P.; Grieve, C.; Laraque, L.; Joseph, A.; Mahajan, N.; Matasar, M.; Straus, D.; Zelenetz, A.; Hamlin, P. |
| Abstract Title: | Phase I study of bendamustine, rituximab, ibrutinib, and venetoclax in relapsed, refractory mantle cell lymphoma |
| Meeting Title: | 16th International Conference on Malignant Lymphoma - Virtual Edition |
| Journal Title: | Hematological Oncology |
| Volume: | 39 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Jun 18-22 |
| Meeting Location: | Virtual |
| ISSN: | 0278-0232 |
| Publisher: | Wiley Blackwell |
| Date Published: | 2021-06-01 |
| Start Page: | 461 |
| End Page: | 462 |
| Language: | English |
| ACCESSION: | 150947697 |
| DOI: | 10.1002/hon.88_2881 |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 34105791 |
| DOI/URL: | |
| Notes: | Meeting Abstract: 375 -- Accession Number: 150947697 -- Entry Date: In Process -- Revision Date: 20210618 -- Publication Type: Article -- Supplement Title: Jun2021 Supplement S2 -- Journal Subset: Biomedical; Europe; Peer Reviewed; UK & Ireland -- NLM UID: 8307268. -- Source: Cinahl |
Altmetric
Citation Impact
BMJ Impact Analytics
